GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelluna ASA (OSTO:ULTIo) » Definitions » Institutional Ownership

Zelluna ASA (OSTO:ULTIO) Institutional Ownership : 0.43% (As of May. 06, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Zelluna ASA Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zelluna ASA's institutional ownership is 0.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zelluna ASA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zelluna ASA's Float Percentage Of Total Shares Outstanding is 0.00%.


Zelluna ASA Institutional Ownership Historical Data

The historical data trend for Zelluna ASA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelluna ASA Institutional Ownership Chart

Zelluna ASA Historical Data

The historical data trend for Zelluna ASA can be seen below:

2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Institutional Ownership 5.84 5.84 4.41 3.69 2.54 2.54 2.52 2.52 0.43 0.43

Zelluna ASA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Zelluna ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Zelluna ASA is a clinical-stage biotechnology company developing novel immunotherapies against cancer and the development of T-Cell Receptor Natural Killer cell therapies for the treatment of solid cancers. The company's current pipeline consists of allogeneic TCR-NK R&D programs ZI-MA4-1, ZI-KL1-1, and ZI-PR-1 targeting well validated antigens expressed across a broad range of solid tumors.

Zelluna ASA Headlines

No Headlines